Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion

Circulation

Volumn 123, Issue 2, 2011, Pages 131-136

  Nagarakanti, Rangadham ^a   Ezekowitz, Michael D ^b   Oldgren, Jonas ^c   Yang, Sean ^d   Chernick, Michael ^b   Aikens, Timothy H ^b   Flaker, Greg ^e   Brugada, Josep ^f   Kamenský, Gabriel ^g   Parekh, Amit ^b   Reilly, Paul A ^h   Yusuf, Salim ^d   Connolly, Stuart J ^d  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

anticoagulants; arrhythmia; atrial fibrillation; cardioversion; stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; CARDIOVERSION; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ELECTRIC STIMULATION THERAPY; HEMORRHAGE; HUMANS; INCIDENCE; RETROSPECTIVE STUDIES; STROKE; WARFARIN;

EID: 78751637313     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.977546     Document Type: Article

References (29)

1. Resnekov L, McDonald L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. Br Heart J. 1967;29:926-936.
2. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. " Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963;269:325-331.
3. Jensen JB, Humphries JO, Kouwenhoven WB, Jude JR. Electroshock for atrial flutter and atrial fibrillation: follow-up studies on 50 patients. JAMA. 1965;194:1181-1184.
4. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19: 851-855.
5. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol. 1989;63:745-746.
6. Steering and Publications committees of the ACUTE Study. Design of a clinical trial for the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE multicenter study). Am J Cardiol. 1998;81: 877-883.
7. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guide- lines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation. 2006;114:e257-3354.
8. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JS, Lip GY, Manning WJ; American College of Chest Physicians. Anti-thrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:546S-592S.
9. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacoki-netics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
10. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563.
11. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-810.
12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
13. Zoll PM, Paul MH, Linenthal AJ, Norman LR, Gibson W. The effects of external electric currents on the heart: control of cardiac rhythm and induction and termination of cardiac arrhythmias. Circulation. 1956;14:745-756.
14. Zoll PM, Linenthal AJ. Termination of refractory tachycardia by external countershock. Circulation. 1962;25:596-603.
15. Paul MH, Miller RA. External electrical termination of supraventricular arrhythmias in congenital heart disease. Circulation. 1962;25:604-609.
16. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. JAMA. 1962;182:548-555.
17. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-216.
18. Roy D, Marchand E, Gagné P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986;112:1039-1043.
19. Ezekowitz MD, Smith EO, Rankin R, Harrison LH Jr, Krous HF. Left atrial mass: diagnostic value of transesophageal 2-dimensional echocardiography and indium-111 platelet scintigraphy. Am J Cardiol. 1983;51: 1563-1564.
20. Manning WJ, Weintraub RM, Waksmonski CA, Haering JM, Rooney PS, Maslow AD, Johnson RG, Douglas PS. Accuracy of transesophageal echocardiography for identifying left atrial thrombi: a prospective, intra-operative study. Ann Intern Med. 1995;123:817-822.
21. Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of trans-esophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol. 1991;17:66-72.
22. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiogra-phy to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-1420. (Pubitemid 32402097)
23. Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonantico-agulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129:71-75.
24. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion Using Enox-aparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of throm-boembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion Using Enoxaparin (ACE) trial. Circulation. 2004;109:997-1003.
25. Executive Steering Committee for the SPORTIF III Investigators. Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared With Warfarin in Patients With Non-Valvular Atrial Fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
26. Albers GW, Diener HC, Frison L, Grind M, M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA. 2005;293:690-698.
27. Halperin JL; Executive Steering Committee, SPORTIF III, and VStudy Investigators. Ximelagatran compared with warfarin for prevention of throm-boembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-438.
28. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419-1426.
29. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-295. (Pubitemid 351508116)